Emily Whitehead

New Capabilities

13 years cancer-free after becoming first pediatric CAR-T recipient

Gene therapy killed Jesse Gelsinger in 1999. His death triggered FDA shutdowns, lawsuits, and nearly ended the field. Fast forward to December 2025: British scientists published results showing that base-edited immune cells—a 'living drug'—achieved deep remissions in 82% of children with previously incurable T-cell leukemia. Three years after treatment, 64% remain disease-free. Some patients are off treatment entirely.

Updated Jan 9